Art Biktarvy denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for art biktarvy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step Therapy to Biktarvy — and Why You Can Appeal

Blue Cross Blue Shield step-therapy ("fail-first") denials for Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) require that the member try one or more formulary-preferred HIV regimens before the plan will cover Biktarvy. For treatment-naive patients, this may mean the plan expects a trial of a different first-line regimen. For treatment-experienced patients, step-therapy requirements may be clinically inappropriate if the patient's history already demonstrates a reason Biktarvy — or its specific component agents — is necessary.

Many states have step-therapy override laws for health plans that require insurers to grant an exception when a prescriber documents that the required prior step is clinically contraindicated, has already been tried, or is otherwise not appropriate. Verify whether your state's law applies to your plan type.

## The Federal Appeal Framework

• ACA §2719 External Review: Available after internal appeal exhaustion, typically within approximately 180 days of the denial notice. Verify the exact deadline on your denial letter.
• ERISA §503 (employer-sponsored plans): Full-and-fair review with written explanation of the specific plan provisions and clinical criteria used.
• Expedited review: If the step-therapy requirement creates a clinically urgent gap in HIV treatment, invoke expedited internal and external review simultaneously — decisions typically required within 72 hours.

## What to Gather

1. Prior antiretroviral history — a complete list of every HIV regimen previously tried, with dates, outcomes, and documented reason for discontinuation (virologic failure, resistance, intolerance, toxicity). 2. Resistance testing records — genotypic or phenotypic resistance test results, if applicable, showing why specific component drugs of the plan's preferred regimen are not appropriate. 3. Prescriber step-therapy override letter — should address each plan-required prior step and explain, for each one, whether it was already tried (with outcome) or why it is clinically inappropriate for this patient. 4. Documentation of current HIV status — most recent relevant lab results from the chart and current clinical assessment. 5. BCBS's step-therapy criteria for Biktarvy — obtain the published policy and address each required step explicitly.

## Criteria-Mapping Structure

| Plan-Required Prior Step Regimen | Status | Documented Reason | |---|---|---| | [Regimen named in plan policy] | Already tried / Contraindicated / Inappropriate | [Chart note, resistance result, prescriber explanation] |

Reference the applicable DHHS HIV treatment guidelines generically to support the prescriber's judgment about regimen selection.

## Next Steps

Request a peer-to-peer review between the treating prescriber and the plan's medical director — this is especially effective for step-therapy denials where the clinical history is complex. File the internal appeal with the full documentation package simultaneously. If the internal appeal is denied, escalate immediately to external review given the clinical urgency of uninterrupted HIV antiretroviral therapy.